Statin induced myopathy epidemiology and demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby
|
Statin induced myopathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Statin induced myopathy epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Statin induced myopathy epidemiology and demographics |
|
FDA on Statin induced myopathy epidemiology and demographics |
|
CDC on Statin induced myopathy epidemiology and demographics |
|
Statin induced myopathy epidemiology and demographics in the news |
|
Blogs on Statin induced myopathy epidemiology and demographics |
|
Risk calculators and risk factors for Statin induced myopathy epidemiology and demographics |
Overview
The prevalence of statin induced myopathy is around 10 to 15%.[1]
Epidemiology and Demographics
The prevalence of statin induced myopathy, described as a spectrum of clinical conditions ranging from myalgia to myositis and rhabdomyolysis, is around 10 to 15%.[1]
References
- ↑ 1.0 1.1 Harper CR, Jacobson TA (2010). "Evidence-based management of statin myopathy". Curr Atheroscler Rep. 12 (5): 322–30. doi:10.1007/s11883-010-0120-9. PMID 20628837.